ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1594

Oral Delivery of Δ9-Tetrahydrocannabinol Provides Symptom and Disease Modification in a Mouse Model of Knee Osteoarthritis

Jason rockel1, Anca Maglaviceanu2, Helena Fetter Filippini3, Ewa Wasilewski4, Melissa M. Lewis-Bakker4, Sarah Gabrial1, Evgeny Rossomacha1, Johana Garcia1, Nizar Mahomed5, Timothy Leroux5, Hance Clarke6, Robert P. Bonin3, Lakshmi P. Kotra7 and Mohit Kapoor1, 1Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada, 2Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 3Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, 4Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 5Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 6Krembil Research Institute, and Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON, Canada, 7Krembil Research Institute, University Health Network; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2023

Keywords: Animal Model, cartilage, Osteoarthritis, pain, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: Abstracts: Osteoarthritis & Joint Biology – Basic Science

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Osteoarthritis (OA) results in joint pain, cartilage degeneration, and synovitis. Recent studies suggest that some OA patients are self-medicating with cannabis. Δ9-tetrahydrocannabinol (THC) is a prominent psychoactive phytocannabinoid in cannabis that can signal in joint cells, including chondrocytes and fibroblast-like synoviocytes (FLS). Currently, no studies link THC to disease modification in OA. We investigated effects and mechanisms of action of THC on pain and disease modification in pre-clinical models of knee OA.

Methods: OA was induced in male C57BL/6 mice by destabilization of the medial meniscus (DMM) or monosodium iodoacetate (MIA; 0.5 mg) and mice were administered THC (0, 1, 5 or 10 mg/kg) orally 5 days/week for 9 or 3 weeks, respectively. Von Frey tests were used to evaluate mechanical allodynia (pain) and open field tests were used to evaluate locomotion and anxiety. DMM knee joints were evaluated for cartilage degeneration/synovitis (OARSI scoring) and Ki67, αSMA, and collagen degradation (C2C) expression (immunohistochemistry). Human FLS and chondrocytes were cultured with 1 mM THC for 48h. RNA was sequenced to determine differentially expressed genes (DEGs; FDR-adjusted p< 0.05; absolute FC≥1.5) and DEG-enriched pathways. Pathway and transcription factor enrichment analyses were used to determine putative cellular mechanisms and transcriptional regulators modified by THC.

Results: In DMM mice, all THC doses reduced cartilage degeneration. 10 mg/kg THC also reduced synovitis (n=14-15/group) and synovial αSMA expression, but not Ki67 or C2C expression (n=6/group). Administration of 5 or 10 mg/kg THC in DMM (n=14-15/group) or MIA (n=10 25/group) mice reduced pain, particularly with 10 mg/kg administration (Fig. 1). Locomotion or anxiety were not modified longitudinally by THC administration. In cultured OA FLS (n=4), RNA sequencing identified 73 DEGs (35 up, 38 down) after treatment with 1 mM THC for 48h compared to vehicle. In cultured OA chondrocytes (n=4), 21 DEGs (9 up, 12 down) were identified after treatment with 1 mM THC compared to vehicle. Computational biology analyses found extracellular matrix (ECM)-related pathways were enriched in the upregulated DEGs in both fibroblasts and chondrocytes, while lipid/steroid/cholesterol-related pathways were enriched in the downregulated DEGs in both cell types. Three genes were commonly upregulated while 5 genes were commonly downregulated in FLS and chondrocytes by THC treatment. From FLS and chondrocyte downregulated DEGs, 22 common putative transcription factors were identified as potential regulators, with SREBF2 as a candidate of interest (Fig. 2).

Conclusion: Oral administration of 10 mg/kg THC reduced cartilage degeneration synovitis and synovial αSMA expression in DMM mouse knee joints, and modified pain in both DMM and MIA OA models. THC treatment of human OA FLS or chondrocytes modified expression of genes associated with ECM and lipid-based pathways, with common genes and putative regulatory transcription factors identified, including SREBF2. We are currently investigating contributions of SREBF2 to effects of THC on joint cells in vitro and mechanisms of pain in vivo.

Supporting image 1

Fig 1. Oral administration of THC attenuates modifies disease progression and pain in OA-induced mice. Sham or DMM mice received treatment by oral gavage 5 days/week with vehicle [veh; medium chain triglyceride (MCT)] or THC (1, 5, 10 mg/kg) for 9 weeks. Knee joints were collected at 10 weeks post-surgery and stained with (A) Safranin O for OARSI scoring of cartilage degeneration and (B) Masson’s Trichrome for synovitis, respectively (n=10_15/group). Data was analyzed by Kruskal-Wallis tests followed by Mann-Whitney post-hoc tests corrected for multiple comparisons using the method of Benjamini, Kreiger and Yekutieli using R v 3.5.03 with coin package v 1.3_24 to account for ties.*, &, or #, q < 0.05 compared to all other comparison groups with different or no symbols. (C) Representative images and quantification of synovial subintima IHC staining for αSMA in knee joint synovium collected from DMM mice given MCT or 10mg/kg THC treatment by oral gavage for 9 weeks (n=6/group). Data was log transformed prior to analysis by Student’s two-tailed t-tests with Welch’s correction. *, p < 0.05. (D) Sham and DMM-surgical mice (n=10_15/group) or (E) saline and MIA-injected mice (n=10_25/group) were administered vehicle (MCT) or 10 mg/kg THC by oral gavage and were evaluated for mechanical allodynia using the von Frey test. (D & E) Data was log-transformed prior to analysis by repeated measures two-way ANOVA followed by multiple comparison’s tests using the method of Benjamini, Kreiger and Yekutieli to correct for false-discovery rate. (D) #, q < 0.0001 in DMM groups vs Sham groups. &, q < 0.01 for DMM + vehicle compared to Sham + vehicle or Sham + THC groups. *, p< 0.05 for all comparisons except between sham groups. (E)#, p < 0.05 for all comparisons except for MIA + saline vs. MIA + THC. ##, p < 0.01 for all comparisons except for MIA + saline vs. MIA + THC. *, p < 0.05 for all comparisons. **, q < 0.05 for all comparison and q < 0.0001 between MIA + vehicle and MIA + THC.

Supporting image 2

Fig 2. RNA Sequencing of THC-treated human OA fibroblast-like synoviocytes (FLS) or chondrocytes identifies differentially expressed genes (DEGs) associated with ECM and lipid metabolism pathways. Human OA FLS and chondrocytes were treated with 1 µM THC and was isolated after 48h and subjected to RNA sequencing. (A) Heat map shows the 73 DEGs from human OA FLS and (B) 21 DEGs from human OA chondrocytes stimulated with 1µM THC compared to vehicle-treated controls (veh; 0.5% DMSO) (n=4/group). (C) Network analysis shows combined transcription factors [determined by analysis through Catrin (http://ophid.utoronto.ca/Catrin/index.jsp] and protein-protein interactions (PPIs) with the overlapping DEGs and linked pathways [identified through analysis using pathdip (http://ophid.utoronto.ca/pathDIP/) and Gene Ontology Annotation analysis] in FLS and chondrocytes after THC treatment compared to vehicle-treated cells. Red nodes with red outlines represent upregulated genes and yellow nodes with purple outlines represent the downregulated genes in both FLS and chondrocytes after THC treatment. Grey lines connect genes to interacting pathways (blue nodes) and blue lines connect genes to predicted upstream TFs (grey nodes). Note SREBF2 is a putitive upstream regulator of common genes downregulated in both OA FLS and chondrocytes.


Disclosures: J. rockel: None; A. Maglaviceanu: None; H. Fetter Filippini: None; E. Wasilewski: None; M. Lewis-Bakker: None; S. Gabrial: None; E. Rossomacha: None; J. Garcia: None; N. Mahomed: AIC, 4, ARTHUR HEALTH CORP, 3; T. Leroux: Depuy Synthes, 2, Smith and Nephew, 2, Stryker, 2; H. Clarke: AbbVie/Abbott, 6, Managing Life, 2, Master Clinician Alliance, 6, Ontario Ministry of Health and Long Term Care, 5, Shoppers Drug Mart, 5; R. Bonin: None; L. Kotra: None; M. Kapoor: None.

To cite this abstract in AMA style:

rockel J, Maglaviceanu A, Fetter Filippini H, Wasilewski E, Lewis-Bakker M, Gabrial S, Rossomacha E, Garcia J, Mahomed N, Leroux T, Clarke H, Bonin R, Kotra L, Kapoor M. Oral Delivery of Δ9-Tetrahydrocannabinol Provides Symptom and Disease Modification in a Mouse Model of Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/oral-delivery-of-%ce%b49-tetrahydrocannabinol-provides-symptom-and-disease-modification-in-a-mouse-model-of-knee-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/oral-delivery-of-%ce%b49-tetrahydrocannabinol-provides-symptom-and-disease-modification-in-a-mouse-model-of-knee-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology